Immutep Ltd 2025 AR2
The report highlights Immutep Limited's transition into a Phase III biotechnology company during the 2025 fiscal year. Key achievements include the initiation of the global registrational Phase III TACTI-004 trial for its lead product candidate, eftilagimod alfa (efti), in first-line non-small cell lung cancer. The company also reported positive clinical data from its TACTI-003 Phase IIb trial in head and neck squamous cell carcinoma and completed enrollment in the AIPAC-003 Phase II trial for metastatic breast cancer. Financially, Immutep maintained a strong balance sheet, ending the fiscal year with A$129.7 million in cash and term deposits.
Company: Immutep Ltd
Sector: Professional & technical services
Country: Australia
Year: 2025
Type: AR2
Pages: 90
Back to company
Immutep Ltd
Annual Report
The report highlights Immutep Limited's transition into a Phase III biotechnology company during the 2025 fiscal year. Key achievements include the initiation of the global registrational Phase III TACTI-004 trial for its lead product candidate, eftilagimod alfa (efti), in first-line non-small cell lung cancer. The company also reported positive clinical data from its TACTI-003 Phase IIb trial in head and neck squamous cell carcinoma and completed enrollment in the AIPAC-003 Phase II trial for metastatic breast cancer. Financially, Immutep maintained a strong balance sheet, ending the fiscal year with A$129.7 million in cash and term deposits.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jul 1, 2024 - Jun 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available